Sensorineural Hearing Loss, Bilateral
1
Pipeline Programs
2
Companies
4
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Eli Lilly and CompanyINDIANAPOLIS, IN
2 programs1
AAVAnc80-hOTOF via Akouos Delivery DevicePhase 1/21 trial
Natural History StudyN/A2 trials
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
Eli Lilly and CompanyAAVAnc80-hOTOF via Akouos Delivery Device
OticonNeuro Cochlear Implant system
Eli Lilly and CompanyNatural History Study
Eli Lilly and CompanyNatural History Study
Clinical Trials (4)
Total enrollment: 372 patients across 4 trials
Gene Therapy Trial for Otoferlin Gene-mediated Hearing Loss
Start: Sep 2023Est. completion: Oct 202822 patients
Phase 1/2Recruiting
Post Approval Study to Assure the ContInued saFety and effectIveness of Neuro Cochlear Implant System in Adult Users
Start: Sep 2025Est. completion: Feb 2029
N/ANot Yet Recruiting
Otoferlin Gene-mediated Hearing Loss Natural History Study
Start: Jul 2022Est. completion: Feb 2029150 patients
N/ARecruiting
Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY)
Start: Jul 2019Est. completion: Apr 2024200 patients
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 actively recruiting trials targeting 372 patients
2 companies competing in this space